Prinses Maxima Centrum voor Kinderoncologie
Prinses Maxima Centrum voor Kinderoncologie is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
Sponsor University Of Cologne
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Sponsor Prinses Maxima Centrum voor Kinderoncologie B.V.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Prinses Maxima Centrum voor Kinderoncologie?
The 2026-10-09 snapshot links Prinses Maxima Centrum voor Kinderoncologie to 8 distinct CTIS trials. Recorded services include Project management, Clinical monitoring, Data management, National Coordinating Center Netherlands, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Prinses Maxima Centrum voor Kinderoncologie?
The most frequently recorded therapeutic areas are Haematological Malignancies, Neurology, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Prinses Maxima Centrum voor Kinderoncologie conducted?
The linked trials record locations in 20 countries, including Germany, Netherlands, Belgium, France, Sweden. These are trial locations, not confirmed office locations or countries where Prinses Maxima Centrum voor Kinderoncologie delivered services.
What can this page tell me about Prinses Maxima Centrum voor Kinderoncologie's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Prinses Maxima Centrum voor Kinderoncologie. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Prinses Maxima Centrum voor Kinderoncologie B.V.